Sunday, December 17, 2006

GPC Biotech Responds to Arbitration Claim by Spectrum Pharmaceuticals

GPC Biotech Responds to Arbitration Claim by Spectrum Pharmaceuticals

MARTINSRIED/MUNICH, Germany, WALTHAM, Mass. and PRINCETON, N.J., Dec 13 GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX 30; Nasdaq: GPCB) announced that on December 12, 2006, the Company was informed by Spectrum Pharmaceuticals, Inc. that Spectrum has filed a Demand for Arbitration and Statement of Claim with the American Arbitration Association to resolve a dispute under the co-development and license agreement for satraplatin. GPC Biotech firmly believes that Spectrum's claims are made in bad faith, are inconsistent with the license agreement, and are completely baseless and without merit.

In its arbitration claim, Spectrum's main allegation is that it is entitled to a payment from GPC Biotech of approximately euro 9.0 million (approximately US$ 12 million). This claim is in connection with an approximately $18 million reimbursement for past development expenses, an approximately $19 million payment for ongoing and future development costs and an additional approximately $22 million commitment for future development related expenses from Pharmion GmbH under the co-development and license agreement between GPC Biotech and Pharmion entered on December 19, 2005. Spectrum also alleges, together with two other claims, that GPC Biotech has not used commercially reasonable efforts to obtain regulatory approval and to promote the distribution of satraplatin in Japan. GPC Biotech will respond to the filing by seeking an affirmative declaration that the Company has not defaulted on any material obligation under the license agreement, will assert various counterclaims against Spectrum in connection with its wrongful conduct, seeking, among other things, damages and attorneys' fees, and will pursue all remedies available under the law. Although Spectrum is seeking a declaration that GPC Biotech's alleged breach provides a basis for termination, GPC Biotech is confident that the dispute will not result in a termination of the co-development and license agreement.

"We believe that the claims made by Spectrum are made in bad faith and are completely baseless and without merit," said Bernd R. Seizinger, M.D., Ph.D., Chief Executive Officer of GPC Biotech. "We will vigorously defend ourselves against these allegations and seek every remedy available to us under the law. We are confident that the dispute will not jeopardize our rights to satraplatin. We therefore are continuing to work aggressively towards completion of the NDA filing in the U.S. by the end of January and will move forward, together with our partner Pharmion, on the application for marketing authorization in Europe. We will also continue to expand our clinical program for satraplatin and to build our commercial infrastructure."

About GPC Biotech

GPC Biotech AG is a publicly traded biopharmaceutical company focused on discovering, developing and commercializing new anticancer drugs. GPC Biotech's lead product candidate - satraplatin - is an oral platinum-based compound that has shown highly statistically significant results for progression-free survival in a Phase 3 registrational trial as a second-line chemotherapy treatment in hormone-refractory prostate cancer. The U.S. FDA has granted fast track designation to satraplatin for this indication, and the rolling NDA submission process for this compound is underway. Satraplatin was in-licensed from Spectrum Pharmaceuticals, Inc. GPC Biotech is also developing a monoclonal antibody with a novel mechanism-of-action against a variety of lymphoid tumors, currently in Phase 1 clinical development, and has ongoing drug development and discovery programs that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany), and its wholly owned U.S. subsidiary has sites in Waltham, Massachusetts and Princeton, New Jersey. For additional information, please visit GPC Biotech's Web site at

This press release contains summary statements relating to the possible outcome of the proceedings and legal actions referenced herein, including the potential remedies available to us. Such statements are forward-looking and are based on current expectations of the management of GPC Biotech and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. We direct you to GPC Biotech's Annual Report on Form 20-F for the fiscal year ended December 31, 2005 and other reports on Form 6-K filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the future results, performance and achievements of GPC Biotech. Forward-looking statements speak only as of the date on which they are made and GPC Biotech does not undertake any obligation to update these forward-looking statements, even if new information becomes available in the future.

Biotech program gets big boost

Biotech program gets big boost

Deseret Morning News - Dec. 17, 2006
Utah high school students may soon know how to produce pesticides from living cells before they even know how to drive.

A $2 million grant to Salt Lake Community College is opening the doors to the biomanufacturing field to high school students with a hands-on lab program at the Granite Technical Institute. The grant, given to 42 community colleges nationwide, will allow SLCC to get students in the field early and get them through a four-year degree.

"We can begin getting students in the pipeline when they are in high school and getting them excited about math,

Sunday, December 10, 2006

George Poste, Director, The Biodesign Institute

Just Announced: George Poste, Director, The Biodesign Institute to Present at R&D Directions’ 4th Annual Drug Development Summit

NEWTOWN, Pa., November 17, 2006 –

R&D Directions is excited to announce a keynote presentation by George Poste, D.V.M., Ph.D., D.Sc., F.R.S., Director, The Biodesign Institute at the Drug Development Summit on January 24, 2007 in Phoenix, AZ. Dr. Poste’s presentation will examine technology’s effect on the business structure of R&D, which new technologies are effective and emerging technologies on the horizon.

Dr. Poste was appointed in May 2003 as the Director of The Biodesign Institute at Arizona State University. In June of 2006, he was awarded the Albert Einstein Award by the Global Business Leadership Council in recognition of outstanding achievement in advancing human health worldwide. He was named ”Scientist of the Year” by R&D Magazine in 2004 in tribute to his incredible past accomplishments and recognition of his leadership in establishing the Biodesign Institute as a confluence of leading edge technologies.

Dr. Poste’s 38-year career has encompassed roles in academia, industry and government, with expertise in disciplines as diverse as molecular biology, pharmaceutical development, and biosecurity. A highly-sought speaker, Poste is engaged by groups as diverse as public health officials, NATO, the U.S. Department of Defense, and the pharmaceutical and biotech industries.

From 1992 to 1999, Dr. Poste was Chief Science and Technology Officer and President of Research & Development for one of the largest pharmaceutical companies in the world, SmithKline Beecham. In an industry where bringing a single drug to market makes careers, Poste oversaw registration of 31 drug, vaccine and diagnostic products. In addition to his academic post, he serves as Chief Executive of Health Technology Networks, a consulting company that specializes in the application of genomic technologies and computing in healthcare.

He is a Fellow of the Royal Society, and the UK Academy of Medicine, a Distinguished Fellow at the Hoover Institution at Stanford University and is a member of the Council for Foreign Relations. In the wake of the 9-11 terrorist attacks, Poste’s expertise was tapped extensively to aid national security. He served as chairman of the task force on bioterrorism for the U.S. Department of Defense, a role he completed in May 2004, and currently serves as a member of the Threat Reduction Advisory Committee for the Defense Threat Reduction Agency.

Dr. Poste will be joined by a distinguished faculty of key industry leaders at the Drug Development Summit. Join us to honor R&D Directions' Top Ten Pipeline Winners, interact with key industry leaders, and network with R&D executives. Hear in-depth knowledge and actionable plans for transforming your R&D operations at the summit. Additional topics to be addressed at the Summit are as follows:

• Cost-Effectiveness through Structural Change
• New Approaches to Adaptive Trial Design
• Avoiding Costly Late-Stage Failures
• Predictive Models to Reduce Attrition
• Post-Marketing Studies
For more information about the Drug Development Summit visit us online at or call 800-437-9997.

Drug Development Summit
Transforming R&D: Experience-Tested Strategies for Increasing Productivity and Innovation
January 21-24, 2007 ? Phoenix, AZ